New | A Multiplexed Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use. #LymeDisease jcm.asm.org/content/early/…
New microfluidic assay (mChip-Ld) detects B.b. antigens: VlsE and a proprietary synthetic 33-mer peptide (PepVF) to capture sensitivity in all disease stages, and OspC for early Lyme disease. Provides results in as little as 15 minutes. #LymeDisease
With specificity set at 95%, the sensitivity of mChip-Ld ranged between 80% (95% CI: 56% to 94%) and 85% (95% CI: 74% to 96%) for two panels of early Lyme disease, and was 100% (95% CI: 83% to 100%) for Lyme arthritis.
For comparison, the standard two-tier test (STT) algorithm detected the same two panels of early Lyme disease with a sensitivity of 48.5% and 75%, Lyme arthritis with a sensitivity of 100%, with a specificity of 97.5% to 100%.
“It will help so many people if we can develop a single, rapid, multiplexed diagnostic test to identify Lyme disease stage that can be used in doctors’ offices.” goodnewsnetwork.org/scientists-dev…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.